Elite in Hyperparathyroidism

Marc G. Vervloet

Nijmegen, GE, NL 
Elite in Hyperparathyroidism
Nijmegen, GE, NL 
OverviewLocationsClinical Research

Overview

Marc Vervloet practices in Nijmegen, Netherlands. Mr. Vervloet is rated as an Elite expert by MediFind in the treatment of Hyperparathyroidism. His top areas of expertise are Hyperparathyroidism, Calcinosis, Rickets, Kidney Transplant, and Parathyroidectomy.

His clinical research consists of co-authoring 174 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 29 articles in the study of Hyperparathyroidism.

Gender
Male

Locations

Nijmegen, GE, Netherlands
Other Locations
Amsterdam UMC
Amsterdam, NH, Netherlands
Utrecht, UT, Netherlands
Netherlands

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Randomized Controlled Clinical Trial to Assess the Effect of Dapagliflozin on Renal and Cardiovascular Outcomes in Patients With Severe Chronic Kidney Disease
A Randomized Controlled Clinical Trial to Assess the Effect of Dapagliflozin on Renal and Cardiovascular Outcomes in Patients With Severe Chronic Kidney Disease
Enrollment Status: Enrolling_by_invitation
Publish Date: December 04, 2025
Intervention Type: Drug
Study Phase: Phase 3
Non-interventional Study to Investigate the Short and Long Term Real-life Safety, Effectiveness, and Adherence of Velphoro® in Patients With Hyperphosphataemia Undergoing Haemodialysis or Peritoneal Dialysis
Non-interventional Study to Investigate the Short and Long Term Real-life Safety, Effectiveness, and Adherence of Velphoro® in Patients With Hyperphosphataemia Undergoing Haemodialysis or Peritoneal Dialysis
Enrollment Status: Completed
Publish Date: October 01, 2019
Intervention Type: Drug
View 1 Less Clinical Trial

174 Total Publications

Troxerutin is a novel osmotic agent for peritoneal dialysis with protective cardiovascular actions.
Troxerutin is a novel osmotic agent for peritoneal dialysis with protective cardiovascular actions.
Journal: Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
Published: November 13, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Vervloet's expertise for a condition
ConditionClose
View All 19 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile